- Amorphous piretanide, piretanide polymorphs, process for their preparation and their use
-
PCT No. PCT/IB96/00254 Sec. 371 Date Nov. 20, 1997 Sec. 102(e) Date Nov. 20, 1997 PCT Filed Feb. 12, 1996 PCT Pub. No. WO96/26197 PCT Pub. Date Aug. 29, 1996Amorphous piretanide having the following characteristics a) exothermic peaks at about 136 DEG C. and about 209 DEG C., b) an endothermic peak at about 207 DEG C., and c) a melting peak at about 225 DEG C. in differential thermal curves; d) a halopattern without diffraction peak in X-ray powder diffraction analysis; and e) characteristic absorptions at around 1700 cm-1 and 3200-3500 cm-1 in infra-red absorption spectrum, and having a superior solubility around neutrality and a high bioavailability effective in the manner of oral or injection administration. Methods of preparing amorphous piretanide are also described.
- -
-
-
- Novel 4-phenoxy-5-sulfamylbenzoic acid derivatives
-
Novel 3-(butylamino) or (1-pyrrolidinyl)-4-phenoxy-5-sulfamylbenzoic acid derivatives where the butyl group contains either a double bond or a hydroxy, ketone, acid or ester functional group or groups, said compounds being useful as diuretics.
- -
-
-
- 5-Sulfamoylbenzoic acid derivatives carrying a heterocyclic substituent
-
5-Sulfamoylbenzoic acids substituted in 4-position by various substituents and in 3-position by a cyclic amino group having sali-diurectic properties, and a process for their manufacture.
- -
-
-
